Kynurenines as predictors of acute coronary events in the Hordaland Health Study

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 18-24

  Eussen, Simone J P M ^a,b   Ueland, Per Magne ^a,c   Vollset, Stein E ^a,d   Nygård, Ottar ^a,c   Midttun, Øivind ^e   Sulo, Gerhard ^a   Ulvik, Arve ^e   Meyer, Klaus ^e   Pedersen, Eva Ringdal ^a   Tell, Grethe S ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d Norwegian Institute of lic Health   (Norway)

^e BEVITAL AS   (Norway)

Author keywords

Acute coronary events; Inflammation; Kynurenines; Prospective cohort study

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; ANTHRANILIC ACID; KYNURENIC ACID; KYNURENINE; TRYPTOPHAN; XANTHURENIC ACID; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; AMINO ACID ANALYSIS; ARTICLE; CARDIOVASCULAR RISK; COMMUNITY LIVING; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUDDEN DEATH; TANDEM MASS SPECTROMETRY; UNSTABLE ANGINA PECTORIS; AGE; ANGINA PECTORIS; BLOOD; COHORT ANALYSIS; CONFIDENCE INTERVAL; GERIATRIC ASSESSMENT; HEALTH SURVEY; HEART INFARCTION; INDEPENDENT LIVING; METABOLISM; MORTALITY; NONPARAMETRIC TEST; NORWAY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SURVIVAL ANALYSIS;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANGINA PECTORIS; BIOMARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GERIATRIC ASSESSMENT; HEALTH SURVEYS; HUMANS; INDEPENDENT LIVING; KYNURENINE; MALE; MYOCARDIAL INFARCTION; NORWAY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 84929172773     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.03.413     Document Type: Article

References (58)

1. G.K. Hansson, Inflammation, atherosclerosis, and coronary artery disease, N. Engl. J. Med. 352 (2005) 1685-1695.
2. Y. Mandi, L. Vecsei, The kynurenine system and immunoregulation, J. Neural Transm. 119 (2012) 197-209.
3. L. Vecsei, L. Szalardy, F. Fulop, J. Toldi, Kynurenines in the CNS: recent advances and new questions, Nat. Rev. Drug Discov. 12 (2013) 64-82.
4. D. Fuchs, P. Avanzas, R. Arroyo-Espliguero, M. Jenny, L. Consuegra-Sanchez, J.C. Kaski, The role of neopterin in atherogenesis and cardiovascular risk assessment, Curr. Med. Chem. 16 (2009) 4644-4653.
5. K. Schroecksnadel, B. Frick, C. Winkler, D. Fuchs, Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease, Curr. Vasc. Pharmacol. 4 (2006) 205-213.
6. H. Mangge, I. Stelzer, E.Z. Reininghaus, D. Weghuber, T.T. Postolache, D. Fuchs, Disturbed tryptophan metabolism in cardiovascular disease, Curr. Med. Chem. 21 (2014) 1931-1937.
7. J.E. McLaren, D.P. Ramji, Interferon gamma: a master regulator of atherosclerosis, Cytokine Growth Factor Rev. 20 (2009) 125-135.
8. P. Niinisalo, N. Oksala, M. Levula, et al, Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study, Ann. Med. 42 (2010) 55-63.
9. B. Wirleitner, V. Rudzite, G. Neurauter, et al, Immune activation and degradation of tryptophan in coronary heart disease, Eur. J. Clin. Investig. 33 (2003) 550-554.
10. Y. Ozkan, M.K. Sukuroglu, M. Tulmac, U. Kisa, B. Simsek, Relation of kynurenine/tryptophan with immune and inflammatory markers in coronary artery disease, Clin. Lab. 60 (2014) 391-396.
11. E.R. Pedersen, O. Midttun, P.M. Ueland, et al, Systemic markers of interferon-gamma-mediated immune activation and long-term prognosis in patients with stable coronary artery disease, Arterioscler. Thromb. Vasc. Biol. 31 (2011) 698-704.
12. G. Sulo, S.E. Vollset, O. Nygard, et al, Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study, Int. J. Cardiol. 168 (2013) 1435-1440.
13. E.R. Pedersen, G.F. Svingen, H. Schartum-Hansen, et al, Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography, Eur. Heart J. 34 (2013) 2689-2696.
14. A. Gonzalez, N. Varo, E. Alegre, A. Diaz, I. Melero, Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach, Adv. Clin. Chem. 45 (2008) 155-197.
15. L.M. Henderson, R.E. Koski, F. D'Angeli, The role of riboflavin and vitamin B6 in tryptophan metabolism, J. Biol. Chem. 215 (1955) 369-376.
16. D. Theofylaktopoulou, A. Ulvik, O. Midttun, et al, Vitamins B2 and B6 as determinants of kynurenines and related markers of interferon-γ-mediated immune activation in the community-based Hordaland Health Study, Br. J. Nutr. 112 (2014) 1065-1072.
17. S. Christen, E. Peterhans, R. Stocker, Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases, Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 2506-2510.
18. Y. Wang, H. Liu, G. McKenzie, et al, Kynurenine is an endothelium-derived relaxing factor produced during inflammation, Nat. Med. 16 (2010) 279-285.
19. B.E. Vikse, S.E. Vollset, G.S. Tell, H. Refsum, B.M. Iversen, Distribution and determinants of serum creatinine in the general population: the Hordaland Health Study, Scand. J. Clin. Lab. Invest. 64 (2004) 709-722.
20. H. Refsum, E. Nurk, A.D. Smith, et al, The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease, J. Nutr. 136 (2006) 1731S-1740S.
21. G. Sulo, J. Igland, S.E. Vollset, O. Nygard, N. Oyen, et al, Cardiovascular disease and diabetes mellitus in Norway during 1994-2009 CVDNOR - a nationwide research project, Nor. Epidemiol. 23 (2013) 101-107.
22. J. Igland, G.S. Tell, M. Ebbing, O. Nygard, S.E. Vollset, et al, Cardiovascular Disease in Norway 1994-2009. Description of Data and Data Quality, University of Bergen, 2013. (Available: http://cvdnor.b.uib.no/files/2013/08/CVDNOR-Data-and-Quality-Report1.pdf).
23. Diagnosis and classification of diabetes mellitus, Diabetes Care 35 (Suppl. 1) (2012) S64-S71.
24. F.C. Brosius III, T.H. Hostetter, E. Kelepouris, et al, Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation, Hypertension 48 (2006) 751-755.
25. O. Midttun, S. Hustad, P.M. Ueland, Quantitative profiling of biomarkers related to B-vitamin status, tryptophan metabolism and inflammationinhuman plasmabyliquid chromatography/tandem mass spectrometry, Rapid Commun. Mass Spectrom. 23 (2009) 1371-1379.
26. K. Meyer, P. Ueland, Targeted quantification of c-reactive protein and cystatin c and its variants by immuno-MALDI-MS, Anal. Chem. 86 (2014) 5807-5814.
27. K.R. Hess, Graphical methods for assessing violations of the proportional hazards assumption in Cox regression, Stat. Med. 14 (1995) 1707-1723.
28. P.K. Andersen, R.B. Geskus, T. de Witte, H. Putter, Competing risks in epidemiology: possibilities and pitfalls, Int. J. Epidemiol. 41 (2012) 861-870.
29. J.M. Satagopan, L. Ben-Porat, M. Berwick, M. Robson, D. Kutler, A.D. Auerbach, A note on competing risks in survival data analysis, Br. J. Cancer 91 (2004) 1229-1235.
30. M.J. Pencina, R.B. D'Agostino Sr., E.W. Steyerberg, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers, Stat. Med. 30 (2011) 11-21.
31. R. Ihaka, R. Gentleman, R: a language for data analysis and graphics, J. Comput. Graph. Stat. 5 (1996) 299-314.
32. D. Theofylaktopoulou, O. Midttun, A. Ulvik, et al, A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study, Clin. Exp. Immunol. 173 (2013) 121-130.
33. S. Pant, A. Deshmukh, G.S. Gurumurthy, et al, Inflammation and atherosclerosis - revisited, J. Cardiovasc. Pharmacol. Ther. 19 (2014) 170-178.
34. M. Sallee, L. Dou, C. Cerini, S. Poitevin, P. Brunet, S. Burtey, The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease, Toxins (Basel) 6 (2014) 934-949.
35. C.L. Eastman, T.R. Guilarte, The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine, Neurochem. Res. 15 (1990) 1101-1107.
36. G.I. Giles, C.A. Collins, T.W. Stone, C. Jacob, Electrochemical and in vitro evaluation of the redox-properties of kynurenine species, Biochem. Biophys. Res. Commun. 300 (2003) 719-724.
37. L.E. Goldstein, M.C. Leopold, X. Huang, et al, 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction, Biochemistry 39 (2000) 7266-7275.
38. T.W. Stone, N. Stoy, L.G. Darlington, An expanding range of targets for kynurenine metabolites of tryptophan, Trends Pharmacol. Sci. 34 (2013) 136-143.
39. C.L. Allen, U. Bayraktutan, Oxidative stress and its role in the pathogenesis of ischaemic stroke, Int. J. Stroke 4 (2009) 461-470.
40. M. Pertovaara, A. Raitala, T. Lehtimaki, et al, Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality, Mech. Ageing Dev. 127 (2006) 497-499.
41. P. Niinisalo, A. Raitala, M. Pertovaara, et al, Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study, Scand. J. Clin. Lab. Invest. 68 (2008) 767-770.
42. I. Wolowczuk, B. Hennart, A. Leloire, et al, Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone, Am. J. Physiol. Regul. Integr. Comp. Physiol. 303 (2012) R135-R143.
43. Y. Kotake, T. Ueda, T. Mori, S. Igaki, M. Hattori, Abnormal tryptophan metabolism and experimental diabetes by xanthurenic acid (XA), Acta Vitaminol. Enzymol. 29 (1975) 236-239.
44. M. Khattab, M. Abul-Fadl, A. Khalafallah, S. Hamza, Studies on the urinary excretion of certain tryptophan metabolites in diabetics, J. Egypt. Med. Assoc. 55 (1972) 531-541.
45. K.S. Rogers, S.J. Evangelista, 3-Hydroxykynurenine, 3-hydroxyanthranilic acid, and o-aminophenol inhibit leucine-stimulated insulin release from rat pancreatic islets, Proc. Soc. Exp. Biol. Med. 178 (1985) 275-278.
46. F.M. van der Kloet, F.W. Tempels, N. Ismail, et al., Discovery of early-stage bio-markers for diabetic kidney disease using ms-based metabolomics (FinnDiane study), Metabolomics 8 (2012) 109-119.
47. L.O. Li, Y.F. Hu, L. Wang, M. Mitchell, A. Berger, R.A. Coleman, Early hepatic insulin resistance in mice: a metabolomics analysis, Mol. Endocrinol. 24 (2010) 657-666.
48. G. Oxenkrug, Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways, Mol. Neurobiol. 48 (2013) 294-301.
49. S.M. Grundy, J.I. Cleeman, S.R. Daniels, et al, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation 112 (2005) 2735-2752.
50. L. Zhang, O. Ovchinnikova, A. Jonsson, et al, The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice, Eur. Heart J. 33 (2012) 2025-2034.
51. S. Christen, S.R. Thomas, B. Garner, R. Stocker, Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway, J. Clin. Invest. 93 (1994) 2149-2158.
52. M. Pertovaara, A. Raitala, M. Juonala, et al, Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study, Clin. Exp. Immunol. 148 (2007) 106-111.
53. S.R. Seshasai, S. Kaptoge, A. Thompson, et al, Diabetes mellitus, fasting glucose, and risk of cause-specific death, N. Engl. J. Med. 364 (2011) 829-841.
54. S.A. Sarkar, R. Wong, S.I. Hackl, et al, Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets, Diabetes 56 (2007) 72-79.
55. C.D. Weaver, T.L. Yao, A.C. Powers, T.A. Verdoorn, Differential expression of glutamate receptor subtypes in rat pancreatic islets, J. Biol. Chem. 271 (1996) 12977-12984.
56. E.R. Pedersen, N. Tuseth, S.J. Eussen, et al, Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 455-462.
57. S. Cheng, E.P. Rhee, M.G. Larson, et al, Metabolite profiling identifies pathways associated with metabolic risk in humans, Circulation 125 (2012) 2222-2231.
58. N. Oyen, O. Nygard, J. Igland, et al, Hospital admission rates for cardiovascular diseases in Western Norway, 1992-2001, Tidsskr. Nor. Laegeforen. 128 (2008) 17-23.